About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

The Effect of Periodontal Treatment on Psoriasis

Clinicaltrials.gov identifier NCT03939936

Recruitment Status Completed

First Posted May 7, 2019

Last update posted May 9, 2019

Study Description

Brief summary:

There is a relationship between psoriasis and periodontal disease. This relationship may be double-sided.

  • Condition or Disease:Periodontal Diseases
  • Intervention/Treatment: Other: Psoriatic measurements
    Other: Non-surgical periodontal treatment
    Other: saliva samples
  • Phase: N/A
Detailed Description

The aim of this randomized controlled clinical study was to determine the effect of non-surgical mechanical periodontal treatment on psoriasis. The study population consisted of 92 periodontitis patients with psoriasis who had untreated periodontal disease. Two randomized groups were formed from these patients. Immediate periodontal treatment (test group, n = 46) and delayed periodontal treatment (control group, n = 46). Clinical periodontal measures, saliva interleukin 2, interleukin 6 and secretory immunoglobulin A levels and PASI scores were performed at baseline and 8th week in control and test group.

Study Design
  • Study Type: Interventional
  • Actual Enrollment: 92 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Prevention
  • Official Title: Effects of Non-surgical Periodontal Therapy on Inflammatory Markers of Psoriasis
  • Actual Study Start Date: May 2017
  • Actual Primary Completion Date: January 2018
  • Actual Study Completion Date: February 2018
Arms and interventions
Arm Intervention/treatment
Placebo Comparator: Control Group
Psoriatic measurements and saliva samples were taken from periodontal disease patients at the baseline and after 8 weeks without the periodontal treatment. Intervention: Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken.
Other: Psoriatic measurements
Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.

Other: saliva samples
Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
Active Comparator: Test Group
Psoriatic measurements and saliva samples were taken from periodontal disease patients before treatment and after 8 weeks. Intervention: Non-surgical periodontal treatment was performed and the Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken.
Other: Psoriatic measurements
Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.

Other: Non-surgical periodontal treatment
Non-surgical periodontal treatment was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.

Other: saliva samples
Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
Outcome Measures
  • Primary Outcome Measures: 1. Proinflammatory cytokines [ Time Frame: Baseline and after 8 weeks ]
    The changes in proinflammatory cytokines levels within 8 weeks. Higher values represent a worse outcome. The decrease in proinflammatory cytokines levels is expected after periodontal treatment.
  • Secondary Outcome Measures: 1. Gingival index [ Time Frame: Baseline and after 8 weeks ]
    The changes in gingival index level after periodontal treatment. Gingival index was measured for determining the severity of disease and clinical outcome. Higher values represent a worse outcome. After periodontal treatment, a reduction in gingival index value is expected.
  • 2. PASI index [ Time Frame: Baseline and after 8 weeks ]
    The changes in PASI index level after periodontal treatment. PASI index was measured for determining the severity of psoriasis disease. Higher values represent a worse outcome. After periodontal treatment, a reduction in PASI index value is expected.
Eligibility Criteria
  • Ages Eligible for Study: 18 to 60 Years (Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- the presence at least 20 remaining teeth,

- the presence of Stage I or Stage II Periodontitis,

- the presence of diagnosed psoriasis.

Exclusion Criteria:

- patients who had the immune-inflammatory disease and require antibiotic prophylaxis,

- patients who received periodontal treatment prior to 6 months,

- women who were breastfeeding or pregnant,

- patients using medicines such as antibiotics, anti-inflammatory drugs,
immune-suppressants.

Contacts and Locations
Contacts
Locations

Turkey
Gaziosmanpasa University
Tokat

Sponsors and Collaborators

Ozge Gokturk

Investigators

Principal Investigator: Atiye Ogrum Gaziosmanpasa Universty

More Information
  • Responsible Party: Ozge Gokturk
  • ClinicalTrials.gov Identifier: NCT03939936 History of Changes
  • Other Study ID Numbers: 17-KAEK-44
  • First Posted: May 7, 2019 Key Record Dates
  • Last Update Posted: May 9, 2019
  • Last Verified: May 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Ozge Gokturk: Psoriasis
  • Additional relevant MeSH terms: Psoriasis Periodontal Diseases